Scientists overturned a core immunology belief by demonstrating that immune cells can attack cancer even when tumors shut down the MHC I molecule, a key pathway for displaying abnormal proteins to the immune system. The discovery reveals a previously unrecognized anti-tumor mechanism.
MHC I downregulation has been viewed as a major escape strategy allowing cancers to evade T cell recognition. Finding alternative immune attack routes could inform immunotherapy combinations for tumors resistant to checkpoint inhibitors.
The research team identified signaling and cell-type interactions enabling killing despite absent MHC I presentation. Laboratory validation was followed by exploration of whether the pathway operates in human tumor samples.
Cancer immunology has expanded rapidly as therapies harness immune cells against malignancies. This pathway discovery adds complexity to models predicting which patients will respond to existing treatments and which require novel approaches.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/health_medicine/